GSK317354A
GSK317354A is a ROCK and GRK inhibitor. GSK317354A can be used for heart failure and Parkinson’s disease research.
For research use only. We do not sell to patients.
- CAS No.: 874119-13-8
- Formula: C25H18F4N6O
- Molecular Weight:494.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10067
Y-33075ROCK Inhibitor -
HY-12798B
Netarsudil hydrochlorideROCK/NET Inhibitor -
HY-10069
Y-33075 dihydrochlorideROCK Inhibitor -
HY-18990
GSK180736AROCK Inhibitor -
HY-12659
LX7101LIM/ROCK/PKA Inhibitor -
HY-125639
(rac)-AR-13503ROCK/PKC Inhibitor -
HY-110339
RKI-1447 dihydrochlorideROCK Inhibitor -
HY-122011
PF-4950834Rho Inhibitor -
HY-153011
ROCK-IN-5ROCK/ERK/GSK/AGC Inhibitor -
HY-100035
PT-262ROCK Inhibitor -
HY-15720B
Glycyl H-1152 hydrochlorideROCKII Inhibitor -
HY-10067R
Y-33075 (Standard)ROCK Inhibitor
Biological Activity
Description
IC50 & Target
|
ROCK |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
75 nM
Compound: 16
|
Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA
Inhibition of human recombinant ROCK1 kinase expressed in insect Sf9 cells by SPA
|
[PMID: 18842034] |
Chemical Information
-
CAS No. 874119-13-8
-
Molecular Weight 494.44
-
Formula C25H18F4N6O
-
SMILES
O=C(C1=C(C)NC(C2=CC=C(C(F)(F)F)N=C2)=NC1C3=CC=C(F)C=C3)NC4=CC5=C(NN=C5)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GSK317354A Related Classifications
HY-111239 Related Classifications
Powered by Bioz